Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

AMLX

Amylyx Pharmaceuticals (AMLX)

Amylyx Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AMLX
DateTimeSourceHeadlineSymbolCompany
03/05/20253:35PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
03/05/20253:32PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
03/05/20253:32PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
03/04/20253:06PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AMLXAmylyx Pharmaceuticals Inc
03/04/20256:30AMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:AMLXAmylyx Pharmaceuticals Inc
03/04/20255:24AMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:AMLXAmylyx Pharmaceuticals Inc
03/04/20255:14AMEdgar (US Regulatory)Form POSASR - Post-effective Amendment to an automatic shelf registration statementNASDAQ:AMLXAmylyx Pharmaceuticals Inc
03/04/20255:07AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMLXAmylyx Pharmaceuticals Inc
02/26/20253:35PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
02/25/20258:00AMBusiness WireAmylyx Pharmaceuticals to Participate in Upcoming March Investor ConferencesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
02/24/20258:00AMBusiness WireAmylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025NASDAQ:AMLXAmylyx Pharmaceuticals Inc
02/14/20253:30PMEdgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:AMLXAmylyx Pharmaceuticals Inc
02/10/20258:00AMBusiness WireAmylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceNASDAQ:AMLXAmylyx Pharmaceuticals Inc
02/06/20257:17PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
02/05/20253:58PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
02/05/20253:55PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
02/05/20253:54PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
01/21/20258:00AMBusiness WireAmylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral SclerosisNASDAQ:AMLXAmylyx Pharmaceuticals Inc
01/10/20254:23PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMLXAmylyx Pharmaceuticals Inc
01/10/20254:13PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AMLXAmylyx Pharmaceuticals Inc
01/10/20257:26AMBusiness WireAmylyx Pharmaceuticals Announces Pricing of Public Offering of Common StockNASDAQ:AMLXAmylyx Pharmaceuticals Inc
01/10/20255:05AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AMLXAmylyx Pharmaceuticals Inc
01/09/20256:30PMBusiness WireAmylyx Pharmaceuticals Announces Proposed Public Offering of Common StockNASDAQ:AMLXAmylyx Pharmaceuticals Inc
01/08/20254:29PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
01/08/20254:26PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AMLXAmylyx Pharmaceuticals Inc
01/06/20258:00AMBusiness WireAmylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial OfficerNASDAQ:AMLXAmylyx Pharmaceuticals Inc
12/30/20246:50AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:AMLXAmylyx Pharmaceuticals Inc
12/04/20246:30AMBusiness WireAmylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric HypoglycemiaNASDAQ:AMLXAmylyx Pharmaceuticals Inc
11/27/20248:00AMBusiness WireAmylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx ConferenceNASDAQ:AMLXAmylyx Pharmaceuticals Inc
11/07/20247:22AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AMLXAmylyx Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:AMLX